Title : Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE.

Pub. Date : 2021 Aug

PMID : 33932503






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 PATIENTS AND METHODS: KATHERINE enrolled HER2-positive EBC patients with residual invasive disease in the breast/axilla at surgery after NACT containing a taxane (+-anthracycline, +-platinum) and trastuzumab (+-pertuzumab). Platinum erb-b2 receptor tyrosine kinase 2 Homo sapiens